Evaluation of venous thromboembolic event prophylaxis in hospitalized cancer patients: A single-centered retrospective study
Evaluation of venous thromboembolic event prophylaxis in hospitalized cancer patients: A single-centered retrospective study

Mehdi Mohammadi; Sholeh Ebrahimpour; Zahra Jahangard-Rafsanjani

Volume 8, Issue 1 , January 2019, , Pages 25-28

Abstract
  Venous thromboembolic events (VTEs) are one of the main causes of death in cancer patients. About one-third of newly diagnosed VTEs are later proved to be associated with cancers. Attempts ...  Read More
Management of febrile neutropenia: A description of clinical and microbiological findings by focusing on risk factors and pitfalls
Management of febrile neutropenia: A description of clinical and microbiological findings by focusing on risk factors and pitfalls

Fatemeh Karimi; Farzaneh Ashrafi; Azadeh Moghaddas; Ali Derakhshandeh

Volume 7, Issue 3 , July 2018, , Pages 147-156

Abstract
   Febrile neutropenia (FN) is one of the most serious clinical problems in patients with hematologic malignancies and patients receiving chemotherapy. The present study was implemented ...  Read More
Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?

Azadeh Moghaddas; Ali Borhani

Volume 5, Issue 4 , October 2016, , Pages 227-233

Abstract
  The National Comprehensive Cancer Network (NCCN) has recommended Ado-trastuzumab emtansine (T-DM1) as a preferred agent for patients with human epidermal growth factor receptor-2 (HER2)-positive ...  Read More